<DOC>
	<DOCNO>NCT00904670</DOCNO>
	<brief_summary>The objective study establish optimal dose Quillivant XR oral suspension would result significant reduction sign symptom ADHD compare placebo treatment pediatric patient age 6-12 year ADHD .</brief_summary>
	<brief_title>Quillivant Oral Suspension ( Quillivant XR ) Treatment Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Male female 6 12 year age time screening , inclusive . Diagnosis ADHD Psychiatrist , Psychologist , Developmental Pediatrician , Pediatrician meeting diagnostic criterion ADHD ( DSMIV ) . A Schedule Affective Disorders Schizophrenia School Age Children ( KSADS ) 16 administered subject assist diagnostic process . A clinicianadministered Clinical Global Impression Severity ( CGIS ) score 3 great . An Attention Deficit Hyperactivity Disorder Rating Scale ( ADHDRS ) score screen baseline great equal 90th percentile normative value gender age least one follow category : hyperactiveimpulsive subscale , inattentive subscale total score . Subject must need pharmacological treatment ADHD . Subjects take medication control ADHD time screen must experience suboptimal efficacy , safety tolerability issue need longacting liquid formulation . For subject take daily medication screen aside ADHD medication : parent legal guardian agree would elective change subject 's medication study ( 10 week total ) . Excluded comorbid psychiatric diagnosis : DSMIV Axis I diagnosis ( active ) ADHD , exception Specific Phobias , Learning Disorders , Motor Skills Disorders , Communication Disorders , Oppositional Defiant Disorder , Elimination Disorders , Sleep Disorders , Adjustment Disorders . Clinically significant cognitive impairment assess clinical judgment Investigator . In case clear , study staff permit administer Wechsler Abbreviated Scale Intelligence ( WASI ) 17 estimate intelligence quotient ( IQ ) . Significant cognitive impairment protocol define estimate IQ 80 . Subjects chronic medical illness include seizure disorder ( exclude history febrile seizure ) , severe hypertension , thyroid disease , structural cardiac disorder , serious cardiac condition , serious arrhythmia , cardiomyopathy , glaucoma , Tourette 's Disorder , family history Tourette 's Disorder tic . Use monoamine oxidase inhibitor within 30 day screen visit . Use psychotropic medication ( except sedative hypnotic prescribe sleep aid stable dose least 30 day prior screen , bedtime ) . Use stimulant medication control ADHD screening permit inclusion criterion number 6 met .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Hyperactivity Attention Deficit Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>Pediatric Patients</keyword>
	<keyword>Quillivant</keyword>
	<keyword>methylphenidate</keyword>
</DOC>